Published Technical Disclosure Archive

Personalized Influenza Vaccination System with Integrated AI, IoT, and Blockchain Technologies

Publication ID: 24-11857618_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Influenza Vaccination System with Integrated AI, IoT, and Blockchain Technologies,” Published Technical Disclosure No. 24-11857618_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857618_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,618.

Summary of the Inventive Concept

A comprehensive system integrating AI-driven predictive modeling, IoT-enabled wearable devices, blockchain-secured electronic health records, and synergistic vaccine formulations to optimize influenza vaccination efficacy in elderly populations.

Background and Problem Solved

The original patent addressed the limitations of traditional influenza vaccines in elderly populations by using saponins and agonists of the intracellular stimulator of interferon genes pathway. However, the new inventive concept tackles the broader challenge of personalized vaccine efficacy by incorporating cutting-edge technologies to enhance immune response, track patient data, and ensure vaccine authenticity.

Detailed Description of the Inventive Concept

The system consists of a database of patient genomic data, an AI-powered predictive model identifying high-risk patients, and a vaccine formulation comprising an influenza vaccine and a mixture of purified Quillaja saponins QA-7, QA-17, QA-18, and QA-21. The IoT-enabled wearable device monitors immune response and transmits data to a cloud-based server for AI-driven analytics. The blockchain-based platform tracks and verifies vaccine authenticity, ensuring compliance with regulatory standards. The composite material for vaccine delivery enhances immune response and provides sustained release of the saponins.

Novelty and Inventive Step

The new claims introduce a novel combination of AI, IoT, blockchain, and synergistic vaccine formulations, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for personalized influenza vaccination.

Alternative Embodiments and Variations

Alternative embodiments may include using different AI algorithms, incorporating additional IoT devices, or substituting the blockchain platform with other decentralized ledger technologies. Variations may include adapting the system for other vaccine types or expanding the predictive model to incorporate additional patient data.

Potential Commercial Applications and Market

The personalized influenza vaccination system has significant commercial potential in the healthcare and biotechnology industries, particularly in the elderly care and vaccine development sectors. The system's ability to optimize vaccine efficacy and ensure authenticity can lead to improved public health outcomes and reduced healthcare costs.

CPC Classifications

SectionClassGroup
A A61 A61K39/145
A A61 A61K39/39
A A61 A61P31/16
A A61 A61K2039/55
A A61 A61K2039/55555
A A61 A61K2039/55561
A A61 A61K2039/55577

Field of Art

Vaccine development, immunology, and medical informatics with a focus on geriatric vaccination technologies and personalized medical systems

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biomedical engineering, immunology, or medical informatics, possessing expertise in vaccine design, AI-driven healthcare technologies, and understanding of immune response modulation techniques

Obviousness Rationale

A PHOSITA would recognize that integrating AI, IoT, and blockchain technologies with existing vaccine formulation techniques represents a predictable extension of known medical informatics approaches. The use of Quillaja saponins as an immune response enhancer is directly derived from the source patent, and the additional technological layers represent standard engineering design choices for personalizing medical interventions. The combination of known elements produces no unexpected results that would suggest non-obviousness.

Obvious Combinations & Variations

Source Patent Element
Influenza vaccine formulation using Quillaja saponins for elderly populations
PTD Variation
AI-powered predictive model for identifying high-risk patients and optimizing vaccine delivery
Obviousness Reasoning
Applying predictive analytics to medical interventions is a known technique, and a PHOSITA would recognize the utility of using AI to enhance existing vaccination strategies
Source Patent Element
Intramuscular vaccine administration for immune response enhancement
PTD Variation
IoT-enabled wearable device for monitoring immune response and tracking vaccine efficacy
Obviousness Reasoning
Continuous patient monitoring is a predictable technological extension for medical interventions, representing a standard design improvement in personalized healthcare
Source Patent Element
Vaccine composition using specific Quillaja saponins
PTD Variation
Composite material with biodegradable polymer matrix and nanoparticle-based adjuvant
Obviousness Reasoning
Developing advanced drug delivery systems is a routine engineering task, and a PHOSITA would find the material modifications obvious given known techniques in pharmaceutical formulation
Source Patent Element
Vaccine targeting elderly populations with compromised immune systems
PTD Variation
Blockchain-secured electronic health records for tracking vaccination history
Obviousness Reasoning
Implementing secure, verifiable medical record systems is a predictable technological solution for managing complex healthcare data
35 U.S.C. § 103 Summary: Based on US Patent 11857618's teachings regarding influenza vaccine formulations using Quillaja saponins, the present publication demonstrates that the claimed technological variations would have been obvious to a person having ordinary skill in the art at the time of invention, as the combination represents a predictable application of known techniques in medical informatics and vaccine development with no unexpected results.

Original Patent Information

Patent NumberUS 11,857,618
TitleBoosting immunogenicity of vaccines using saponins and agonists of the intracellular stimulator of interferon genes pathway
Assignee(s)Emory University